---
figid: PMC9688300__cells-11-03637-g003
figtitle: O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty
  Liver Disease
organisms:
- Mus musculus
- Rattus norvegicus
- Hepatitis B virus
- Homo sapiens
- NA
organisms_ner:
- Rattus norvegicus
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
- Danio rerio
- Arabidopsis thaliana
pmcid: PMC9688300
filename: cells-11-03637-g003.jpg
figlink: /pmc/articles/PMC9688300/figure/cells-11-03637-f003/
number: F3
caption: O-GlcNAcylation and NAFL-NASH-liver fibrosis-hepatoma tetralogy. The O-GlcNAcylation
  of the LXR, the ChREBP, and SREBP-1 promoted NAFL formation. O-GlcNAcylated NF-κB
  subunit p65 played a role in the progression of NASH by facilitating inflammatory
  damage, and the O-GlcNAcylated NF-κB subunit c-Rel exerted an anti-inflammatory
  effect. During liver fibrosis, O-GlcNAcylation of collagens accelerated fibrosis,
  while O-GlcNAcylation of the SRF represented anti-fibrotic effects. Finally, O-GlcNAcylated
  RIPK3 contributed to HCC. NAFL, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis;
  LXR, Liver X receptor; carbohydrate-responsive element-binding protein; ChREBP,
  carbohydrate-responsive element-binding protein; SREBP-1, sterol regulatory element-binding
  protein 1; NF-κB, Nuclear factor-κB; SRF, serum response factor; HCC, hepatocellular
  carcinoma; OGT, O-GlcNAc transferase; GFAT, glutamine fructose-6-phosphate amidotransferase;
  ER stress, endoplasmic reticulum stress; HBP, hexosamine biosynthetic pathway; IRE1α,
  inositol requiring enzyme 1α; XBP1, X-box-binding protein 1; PDGFRβ, platelet-derived
  growth factor receptorβ; TFF2, trefoil factor 2; JNK, Jun N-terminal kinases.
papertitle: O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty
  Liver Disease.
reftext: Yicheng Zhou, et al. Cells. 2022 Nov;11(22):3637.
year: '2022'
doi: 10.3390/cells11223637
journal_title: Cells
journal_nlm_ta: Cells
publisher_name: MDPI
keywords: O-GlcNAcylation | insulin resistance | non-alcoholic fatty liver disease
  | non-alcoholic steatohepatitis | fibrosis | cirrhosis | hepatocellular carcinoma
automl_pathway: 0.9478977
figid_alias: PMC9688300__F3
figtype: Figure
redirect_from: /figures/PMC9688300__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9688300__cells-11-03637-g003.html
  '@type': Dataset
  description: O-GlcNAcylation and NAFL-NASH-liver fibrosis-hepatoma tetralogy. The
    O-GlcNAcylation of the LXR, the ChREBP, and SREBP-1 promoted NAFL formation. O-GlcNAcylated
    NF-κB subunit p65 played a role in the progression of NASH by facilitating inflammatory
    damage, and the O-GlcNAcylated NF-κB subunit c-Rel exerted an anti-inflammatory
    effect. During liver fibrosis, O-GlcNAcylation of collagens accelerated fibrosis,
    while O-GlcNAcylation of the SRF represented anti-fibrotic effects. Finally, O-GlcNAcylated
    RIPK3 contributed to HCC. NAFL, non-alcoholic fatty liver; NASH, non-alcoholic
    steatohepatitis; LXR, Liver X receptor; carbohydrate-responsive element-binding
    protein; ChREBP, carbohydrate-responsive element-binding protein; SREBP-1, sterol
    regulatory element-binding protein 1; NF-κB, Nuclear factor-κB; SRF, serum response
    factor; HCC, hepatocellular carcinoma; OGT, O-GlcNAc transferase; GFAT, glutamine
    fructose-6-phosphate amidotransferase; ER stress, endoplasmic reticulum stress;
    HBP, hexosamine biosynthetic pathway; IRE1α, inositol requiring enzyme 1α; XBP1,
    X-box-binding protein 1; PDGFRβ, platelet-derived growth factor receptorβ; TFF2,
    trefoil factor 2; JNK, Jun N-terminal kinases.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Mlxipl
  - Ogt
  - Srebf1
  - Syt1
  - Xbp1
  - Samsn1
  - Gfpt1
  - Rel
  - Npc2
  - Srf
  - Pdgfrb
  - Ripk3
  - Tff2
  - Mapk8
  - Nfkb1
  - Jun
  - MLXIPL
  - NR1H2
  - NR1H3
  - OGT
  - EOGT
  - POMGNT1
  - POMGNT2
  - SREBF1
  - ERN1
  - RELA
  - SYT1
  - GORASP1
  - WNK1
  - CD40
  - ARHGEF7
  - ASCC1
  - H3P40
  - XBP1
  - XBP1P1
  - GFPT1
  - GFPT2
  - REL
  - AZU1
  - HDLBP
  - SLBP
  - STAM2
  - HEBP1
  - SRF
  - PDGFRB
  - RIPK3
  - TFF2
  - MAPK8
  - MAPK9
  - MAPK10
  - NFKB1
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
  - HCC
  - HYCC1
  - JUN
  - FOS
  - FOSB
  - JUNB
  - JUND
  - FOSL1
  - FOSL2
  - Nr1h3
  - Nr1h2
  - Ern1
  - Rela
  - Gorasp1
  - Cdc37
  - Lsp1
  - Pold2
  - Cd40
  - Dctn2
  - Stam2
  - Pipox
  - Mondo
  - sxc
  - SREBP
  - Ire1
  - dl
  - wash
  - Hrb27C
  - betaTub60D
  - Rpt5
  - DCTN2-p50
  - Gfat1
  - mal
  - bs
  - bsk
  - Dif
  - Jra
  - AP-1gamma
  - kay
  - mlxip
  - ogt.1
  - rela
  - nfkb1
  - xbp1
  - rel
  - hdlbpa
  - srfa
  - casp8
  - pdgfrb
  - ripk3
  - mapk8b
  - hccsa.2
  - jun
  - IRE1A
  - GFAT
  - WOL
  - AP1
  - Fibrosis
---
